Compare Genuine Parts Company (GPC) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genuine Parts Company vs Mesoblast Limited — how do they compare? Genuine Parts Company trades at $125.54 (market cap $16.65B), while Mesoblast Limited trades at $19.01 (market cap $2.31B). The key difference: Genuine Parts Company is far larger — about 7.2× Mesoblast Limited's market cap, and Genuine Parts Company pays a 3.51% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| GPC | MESO | |
|---|---|---|
Market Cap | $16.65B | $2.31B |
Sector | Consumer Cyclical | Technology |
52-Week High | $149.26 | $20.96 |
52-Week Low | $92.47 | $11.35 |
Enterprise Value | $22.87B | $2.32B |
Dividend Yield | 3.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Genuine Parts Company (GPC) trades at $122.16, down 1.1% on the day, with a bullish technical signal supported by moving averages and oscillators. Fundamentally, the company shows strong revenue growth to $24.3B in 2025 but faces significant margin compression, with net income plummeting to $66M (0.27% margin) from $904M the prior year. The stock carries a high P/E of 275 but reasonable P/S of 0.68, while analysts maintain a consensus 'Buy' rating with a $133 price target. Recent news highlights GPC's upcoming Q2 2026 earnings report on July 21, 2026, and its status as a Dividend King with 70 consecutive years of dividend increases.
The outlook presents a mixed picture: technical strength and dividend reliability support the stock, while deteriorating profitability and high valuation multiples pose significant risks. Investment opportunity lies in potential earnings recovery and continued dividend growth, but investors face headwinds from margin pressure and elevated P/E ratio requiring careful monitoring of upcoming quarterly results.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
